Participant flow

BEAT-meso: Bevacizumab and Atezolizumab in Malignant Pleural Mesothelioma · Source last updated 2026-07-22

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Atezolizumab 1200mg intravenously on day 1 every 3 weeks plus bevacizumab 15mg/kg intravenously on day 1 every 3 weeks plus 4-6 cycles of carboplatin AUC 5 plus pemetrexed 500mg/m\^2 intravenously on day 1 every 3 weeks

   id

   FG000

   title

   Atezolizumab Plus Bevacizumab Plus Chemotherapy

2. description

   Bevacizumab 15mg/kg intravenously on day 1 every 3 weeks plus 4-6 cycles of carboplatin AUC 5 plus pemetrexed 500mg/m\^2 intravenously on day 1 every 3 weeks

   id

   FG001

   title

   Bevacizumab Plus Chemotherapy

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         145

      2. group Id

         FG001

         num Subjects

         150

      type

      Death

   2. reasons

      1. group Id

         FG000

         num Subjects

         4

      2. group Id

         FG001

         num Subjects

         2

      type

      Withdrawal/Lost to follow-up

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         200

      2. group Id

         FG001

         num Subjects

         200

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         198

      2. comment

         There is one patient assigned in the BC arm who actually received ABC treatment. This patient is evaluated in the treatment arm to which he/she was randomly assigned (BC) for all the efficacy (Intention-to-Treat (ITT)) analyses. For the safety analysis the patient is evaluated according to the treatment he/she received (ABC treatment), irrespective of the allocated treatment at randomization.

         group Id

         FG001

         num Subjects

         200

      type

      Received at least one dose of trial treatment

   3. achievements

      1. group Id

         FG000

         num Subjects

         8

      2. group Id

         FG001

         num Subjects

         4

      comment

      Patients who were on treatment at database cut-off for final efficacy analysis: September 01, 2023

      type

      On treatment

   4. achievements

      1. group Id

         FG000

         num Subjects

         192

      2. group Id

         FG001

         num Subjects

         196

      comment

      Atezolizumab plus bevacizumab plus chemotherapy: 109 progressions, 62 toxicities, 9 deaths, 7 investigator decisions, 1 patient decision, 2 other; Bevacizumab plus chemotherapy: 141 progressions, 35 toxicities, 9 deaths, 1 investigator decision, 2 patient decisions, 8 other

      type

      Treatment failures

   5. achievements

      1. group Id

         FG000

         num Subjects

         2

      2. group Id

         FG001

         num Subjects

         0

      type

      Never started treatment

   6. achievements

      1. group Id

         FG000

         num Subjects

         51

      2. group Id

         FG001

         num Subjects

         48

      comment

      Patients who were on follow-up at database cut-off for final efficacy analysis: September 01, 2023

      type

      COMPLETED

   7. achievements

      1. group Id

         FG000

         num Subjects

         149

      2. group Id

         FG001

         num Subjects

         152

      type

      NOT COMPLETED

   title

   Overall Study

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice